2020 performance

Reports on healthcare service assessments – developed in 1H2020.

Qualification of healthcare services into the health benefit package:

• next-generation whole-exome sequencing in diagnostics of genetic disorders (health problem card 8) in outpatient specialist care;
• clinical exome sequencing (panel of > 4.500 genes with well-documented clinical significance) using next-generation sequencing in diagnostics of genetic disorders (health problem card 5) in outpatient specialist care;
• gene expression profiling (GEP) in oncological diagnostics (health problem card 2) in outpatient specialist care;
• electrochemotherapy (ECT) – verification of recommendation No. 49/2013 of 29.04.2013 on qualification of healthcare services into the health benefit package as part of hospital treatment.

Changes of health technologies:

• in oncology in the following indications: C53, C54, C56 gynaecological neoplasms in primary healthcare, outpatient specialist care, inpatient care;
• C64 – renal cancer in primary healthcare, outpatient specialist care, inpatient care;
• C67 – bladder cancer in primary healthcare, outpatient specialised care, inpatient care;
• Decision problem analysis on changing health technologies in all cardiology guaranteed benefits (I00-I99) in primary healthcare, outpatient specialist care, hospital treatment.

Changes in service provision organisation:

• development (in consultation with stakeholders) of comprehensive oncological care in urooncological neoplasms: kidney cancer, bladder cancer;
• development (in consultation with stakeholders) of a comprehensive oncological care system in gynaecological neoplasms: cervical, endometrial, ovarian malignant cancers;

Other tasks commissioned by the Minister of Health:

• report on validity of introducing check-ups of 60-year-olds as a guaranteed healthcare service;
• report on validity of allowing GPs to commission the following diagnostic tests: ferritin and vitamin D-25-OH levels; Borellia afzelli, Borellia burgdorferi;
• development of a concept for the organisation and scope of preventive examinations for 40-years-olds and older people;
• report on the validity of changing the continuous glycaemic monitoring service: financing Roche’s Eversense system as a guaranteed service;
• report on the validity of financing the following medicinal product from public funds: Jakavi (ruxolitinib) in the indication: chronic mucocutaneous candidiasis (ICD-10: D84.8) with STAT1 and NFC1 mutations – under emergency access to medicines;
• report on validity of financing the following medicinal product from public funds: IMFINZI (durvalumab) in the indication: unresectable non-small cell lung cancer PD-L1 positive (ICD-10: C34) – under emergency access to medicines;
• report on validity of financing the following medicinal product from public funds: Cyramza (ramucirumab) in the indication: generalised gastric adenocarcinoma (ICD-10: C16.8) – under emergency access to medicines;
• report on the rationalisation proposal made by Coloplast Sp. z o.o. and the national consultant in the field of paediatric urology on ensuring greater accessibility to medical devices for disabled children – hydrophilic urinary catheters in the healthcare system in Poland.